Karen L Madsen

List of Publications by Year
in descending order

25 papers	543 citations	686830 13 h-index	642321 23 g-index
25 all docs	25 docs citations	25 times ranked	897 citing authors

#	Article	IF	Citations
1	Bezafibrate in skeletal muscle fatty acid oxidation disorders. Neurology, 2014, 82, 607-613.	1.5	96
2	Late-onset Pompe disease is prevalent in unclassified limb-girdle muscular dystrophies. Molecular Genetics and Metabolism, 2013, 110, 287-289.	0.5	73
3	Training improves oxidative capacity, but not function, in spinal muscular atrophy type III. Muscle and Nerve, 2015, 52, 240-244.	1.0	43
4	Exercise intolerance in Glycogen Storage Disease Type III: Weakness or energy deficiency?. Molecular Genetics and Metabolism, 2013, 109, 14-20.	0.5	38
5	Growth and differentiation factor 15 as a biomarker for mitochondrial myopathy. Mitochondrion, 2020, 50, 35-41.	1.6	38
6	Safety and efficacy of omaveloxolone in patients with mitochondrial myopathy. Neurology, 2020, 94, e687-e698.	1.5	38
7	Fat and carbohydrate metabolism during exercise in late-onset Pompe disease. Molecular Genetics and Metabolism, 2012, 107, 462-468.	0.5	27
8	Skeletal muscle metabolism is impaired during exercise in glycogen storage disease type III. Neurology, 2015, 84, 1767-1771.	1.5	26
9	Patients With Medium-Chain Acylâ€“Coenzyme A Dehydrogenase Deficiency Have Impaired Oxidation of Fat During Exercise but No Effect of<scp>l</scp>-Carnitine Supplementation. Journal of Clinical Endocrinology and Metabolism, 2013, 98, 1667-1675.	1.8	24
10	Creatine kinase response to highâ€intensity aerobic exercise in adultâ€onset muscular dystrophy. Muscle and Nerve, 2013, 48, 897-901.	1.0	23
11	Impaired glycogen breakdown and synthesis in phosphoglucomutase 1 deficiency. Molecular Genetics and Metabolism, 2017, 122, 117-121.	0.5	19
12	No effect of triheptanoin on exercise performance in McArdle disease. Annals of Clinical and Translational Neurology, 2019, 6, 1949-1960.	1.7	17
13	L-Carnitine Improves Skeletal Muscle Fat Oxidation in Primary Carnitine Deficiency. Journal of Clinical Endocrinology and Metabolism, 2018, 103, 4580-4588.	1.8	15
14	Muscle glycogen synthesis and breakdown are both impaired in glycogenin-1 deficiency. Neurology, 2017, 89, 2491-2494.	1.5	13
15	Impaired lipolysis in propionic acidemia: A new metabolic myopathy?. JIMD Reports, 2020, 53, 16-21.	0.7	10
16	Skeletal muscle metabolism during prolonged exercise in Pompe disease. Endocrine Connections, 2017, 6, 384-394.	0.8	8
17	Exercise Testing, Physical Training and Fatigue in Patients with Mitochondrial Myopathy Related to mtDNA Mutations. Journal of Clinical Medicine, 2021, 10, 1796.	1.0	8
18	No effect of resveratrol on fatty acid oxidation or exercise capacity in patients with fatty acid oxidation disorders: A randomized clinical crossâ€over trial. Journal of Inherited Metabolic Disease, 2022, 45, 517-528.	1.7	7

#	Article	IF	Citations
19	Pure exercise intolerance and ophthalmoplegia associated with the m.12,294GÂ>ÂA mutation in the MT-TL2 gene: a case report. BMC Musculoskeletal Disorders, 2017, 18, 419.	0.8	6
20	Fat oxidation is impaired during exercise in lipin-1 deficiency. Neurology, 2019, 93, e1433-e1438.	1.5	6
21	Results of an open label feasibility study of sodium valproate in people with McArdle disease. Neuromuscular Disorders, 2020, 30, 734-741.	0.3	3
22	Impaired fat oxidation during exercise in multiple acyl-CoA dehydrogenase deficiency. JIMD Reports, 2019, 46, 79-84.	0.7	2
23	Impaired Fat Oxidation During Exercise in Long-Chain Acyl-CoA Dehydrogenase Deficiency Patients and Effect of IV-Glucose. Journal of Clinical Endocrinology and Metabolism, 2019, 104, 3610-3613.	1.8	1
24	Energy metabolism during exercise in patients with Î²â€enolase deficiency (GSDXIII). JIMD Reports, 2021, 61, 60-66.	0.7	1
25	No effect of triheptanoin in patients with phosphofructokinase deficiency. Neuromuscular Disorders, 2022, , .	0.3	1